spacer
home > epc > Winter 2016
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2016

   
Text
PDF
bullet
Business and Finance
Drug Prices

Adding Value


Putting a price tag on drugs is a challenge – but by implementing two increasingly common pricing strategies, it is possible to satisfy both seller and buyer, claim ERT’s Stephen Raymond and Matthew Reaney.
 
view
download pdf
bullet
Marketplace & Business
Mergers and Acquisitions

Shared Vision


Dealing with employees is, arguably, the most important aspect of M&A. Mike Straw at Achieve Breakthrough reveals what company executives can do to ensure a smooth transition.
 
view
download pdf
M&A Activity Report

Across the Border


There is a noticeable shift towards acquiring in growing markets overseas, and investment in personalised medicine – EPC summaries these twin trends within M&A activity.
 
view
download pdf
bullet
Legal & Regulatory
Clinical Evaluation

Conform to the Norm: Part 1


In this first of a two-part article, Terry Winchell at GCP Innovative Dynamics offers an in-depth analysis of the FDA clinical investigator disqualification process, including early beginnings and how the FDA interprets its role.
 
view
download pdf
bullet
Electronic Solutions
Pharmacovigilance and Social Media

Keep Talking


Digital media is set to alter the way patients and companies communicate, observes Supriya Desai at Sciformix Corporation, but this change is not without risk.
 
view
download pdf
bullet
Review
Event Review

Latest on Life Sciences


EPC reports on the CMS Global Lifesciences Forum 2015, in which the biggest issues driving the sector were discussed.
 
view
download pdf
bullet
Manufacturing Environment
Medical Device Regulations

Step by Step

Chris Rule
at Maetrics advises medical device manufacturers to take great care in producing clinical evaluation reports, and proposes a 10-step plan to successfully comply with new regulations in 2018.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement